Metraipolis › archive › dc_e2dbf3c82acf
Rilzabrutinib — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/Rilzabrutinib
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-10-07T23:11:40.669Z
- SHA-256 of the archived text
6a661f062c1737d9b766c64a419dad8ebeda355ff6842c1a8bb03caf7829118f- Stable URL of this page
https://metraipolis.com/documento/dc_e2dbf3c82acf
How to cite
Rilzabrutinib — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Rilzabrutinib (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_e2dbf3c82acf (Metraipolis archive dc_e2dbf3c82acf, sha256 6a661f062c1737d9b766c64a419dad8ebeda355ff6842c1a8bb03caf7829118f)
BibTeX
@misc{dce2dbf3c82acf,
title = {Rilzabrutinib — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/Rilzabrutinib},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_e2dbf3c82acf; sha256 6a661f062c1737d9b766c64a419dad8ebeda355ff6842c1a8bb03caf7829118f},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Rilzabrutinib. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Rilzabrutinib, sold under the brand name Wayrilz, is an anti-cancer medication used for the treatment of immune thrombocytopenia. Rilzabrutinib is a tyrosine kinase inhibitor. It is taken by mouth. Rilzabrutinib may increase the risk of serious infections (including bacterial, viral, or fungal). The most common side effects include diarrhea, nausea, headache, abdominal pain, and COVID-19. Rilzabrutinib was approved for medical use in the United States in August 2025. The US Food and Drug Administration considers it to be a first-in-class medication. Tema degli esploratori: scienze della vita e salute (deposito sistematico; categoria «Immunology»). Fonte: Wikipedia in inglese, voce «Rilzabrutinib» — https://en.wikipedia.org/wiki/Rilzabrutinib Wikidata Q135928397 (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q135928397 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Rilzabrutinib?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1365397481, consultata il 2026-10-07T22:50:00.916Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: d248b4a35055359448f8cfabdae70a3384daa4e359ea78584f46ad1c1b8595d6